2024.02.29 MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers Resarch Reports
2023.09.29 MNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model Resarch Reports
2023.08.21 MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury Resarch Reports
2022.08.19 MNOV: Phase 2 Trial of MN-001 in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Underway Resarch Reports
2022.06.13 MNOV: Positive Results for MN-166 (Ibudilast) in Patients at Risk of Acute Respiratory Distress Syndrome Resarch Reports
2022.05.25 MNOV: Plans for Phase 2 Study of MN-001 (tipelukast) in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Resarch Reports
2022.03.01 MNOV: Ibudilast Identified as Promising Development Candidate in Alcohol Use Disorder and Degenerative Cervical Myelopathy Resarch Reports
2021.11.23 MNOV: Addition of MN-166 to PD-1 Treatment Extends Survival in Preclinical GBM Model Resarch Reports
2020.07.02 MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID 19 Patients Resarch Reports
2020.03.12 MNOV: MN-166 to be Developed as a Treatment for Severe Pneumonia and Acute Respiratory Distress Syndrome Resarch Reports
2020.02.25 MNOV: Multiple Trials of MN-166 Ongoing; Recent Price Move Creates Buying Opportunity Resarch Reports
2019.08.14 MNOV: Abstract on MN-166 to be Presented at ALS/MND International Symposium Resarch Reports
